Palopegteriparatide

Introduction Overview

Generic Name

palopegteriparatide

Brand Name

Yorvipath

Dosage Form

prefilled pen for subcutaneous use

Drug Class

Parathyroid hormone and analogs

Pharmacokinetics

Absorption: Yorvipath is administered via subcutaneous injection using a prefilled pen, designed for once-daily dosing. Following subcutaneous administration, palopegteriparatide, a long-acting parathyroid hormone (PTH) analog, exhibits gradual absorption characterized by a sustained release profile that maintains physiological levels of PTH (1-34) throughout the day. Clinical pharmacokinetic studies indicate that this protracted release mitigates the peaks and troughs commonly observed with shorter-acting PTH analogs, enhancing calcium and phosphate homeostasis. The absorption kinetics permit efficient uptake into systemic circulation, leading to stable plasma concentrations that support therapeutic efficacy. Distribution: After absorption, palopegteriparatide distributes into plasma and extracellular fluid compartments. Being a peptide-based hormone analog, distribution is primarily extracellular with minimal intracellular penetration. It does not extensively bind to plasma proteins beyond physiological albumin binding. The volume of distribution is consistent with biologics of similar molecular weight, allowing effective access to target tissues, notably the bone and kidneys where PTH exerts its physiological actions. Research indicates tissue affinity for bone remodeling sites, supporting its clinical role in hypoparathyroidism management. Metabolism: Metabolism of palopegteriparatide occurs predominantly via proteolytic degradation by peptidases and proteases in plasma and peripheral tissues. The prodrug structure designed for sustained release undergoes enzymatic cleavage, liberating active PTH (1-34) fragments that mimic endogenous hormone function. Metabolic clearance is influenced by renal and hepatic enzymatic pathways. Variability in metabolism may occur with changes in organ function, though specific cytochrome P450 involvement is negligible due to the peptide nature of the drug. Elimination: The elimination of palopegteriparatide and its metabolites is primarily renal, with intact and metabolized forms excreted in urine. The elimination half-life is extended compared to native PTH due to the prodrug formulation enabling steady plasma concentrations. The recommended dosing frequency (once daily) reflects this prolonged elimination profile. Clinical studies confirm consistent clearance without accumulation when dosing guidelines are followed. Special considerations for patients with renal impairment have yet to be fully established but monitoring serum calcium and phosphorus levels remains critical to guide therapy and minimize adverse effects.

Dosage Forms

Available Dosage Forms: Yorvipath is supplied in three prefilled pen strengths, each identified by a distinct colored push button and containing multiple doses: - Yorvipath 168 mcg/0.56 mL prefilled pen with blue push button; labeled doses include 6 mcg, 9 mcg, and 12 mcg per injection. - Yorvipath 294 mcg/0.98 mL prefilled pen with orange push button; labeled doses of 15 mcg, 18 mcg, and 21 mcg per injection. - Yorvipath 420 mcg/1.4 mL prefilled pen with burgundy push button; labeled doses of 24 mcg, 27 mcg, and 30 mcg per injection. These pens allow precise dose titration within the therapeutic range and multiple administrations per pen prior to disposal. Dosages for Adults and Adolescents: The recommended starting dose for adults with hypoparathyroidism is 18 mcg administered once daily via subcutaneous injection. Dosage adjustments are made in 3 mcg increments or decrements to maintain serum calcium within the normal physiological range. Providers aim to achieve normocalcemia without the need for supplemental active vitamin D analogs (e.g., calcitriol) or therapeutic doses of elemental calcium exceeding 600 mg/day, though continuation of dietary calcium supplements to meet daily requirements is allowed. The maximum dose recommended is 30 mcg once daily. Should patients fail to maintain appropriate calcium levels at the maximum dose, combination therapy with calcium and/or active vitamin D should be considered. Specific Patient Populations: Yorvipath is not approved for use in pediatric patients or young adults with open epiphyses due to potential risks, including osteosarcoma. There is limited data in patients with renal impairment or hepatic dysfunction; caution and close monitoring are advised. Pregnant or breastfeeding patients should be counseled on the unknown risks, with close monitoring if treatment continuation is deemed necessary. The injection site may be the abdomen or the front of the thigh, with rotation to prevent tissue damage. Each prefilled pen should be discarded 14 days after first use to maintain potency and sterility.

Mechanism Of Action

Yorvipath (palopegteriparatide) is a long-acting parathyroid hormone analog designed to mimic the physiological effects of endogenous PTH by slowly releasing active PTH (1-34) fragments into systemic circulation. Its primary molecular mechanism is activation of PTH receptors (PTH1R) located primarily on osteoblasts in bone and cells in the renal tubules. Activation of PTH1R triggers intracellular signaling cascades involving G protein-coupled pathways, notably the adenylate cyclase-cAMP-protein kinase A (PKA) pathway and phospholipase C-PKC pathway. These cascades modulate gene expression responsible for bone remodeling and calcium homeostasis. At the cellular level, stimulation of osteoblasts by Palopegteriparatide enhances bone formation, indirectly promoting osteoclast differentiation leading to balanced bone resorption, which together maintains skeletal integrity. In the kidneys, PTH1R activation decreases phosphate reabsorption in proximal tubules and increases calcium reabsorption in distal tubules, helping normalize serum calcium and phosphate levels. Biochemically, this results in increased intestinal calcium absorption indirectly through stimulation of renal activation of vitamin D metabolites. Yorvipath's sustained release prodrug design results in prolonged receptor activation compared to native PTH, enabling more stable serum calcium levels and reduced fluctuations associated with short-acting analogs. Clinically, this translates to effective management of hypoparathyroidism symptoms and complications by restoring physiological PTH activity, reducing dependence on high doses of calcium and active vitamin D supplements. Compared to other parathyroid hormone therapies, Yorvipath provides a differentiated pharmacokinetic and pharmacodynamic profile that may improve patient compliance and safety by mitigating risks of hypo- and hypercalcemia. Current research underscores the advantages of pegylated PTH analogs in offering enhanced stability, predictable dosing, and improved therapeutic outcomes, with ongoing studies evaluating long-term safety including risk of osteosarcoma.

Pharmacological Actions

Acts as an analog of parathyroid hormone (PTH), primarily mimicking PTH (1-34) fragment activity.
Stimulates PTH1R receptors on osteoblasts and renal tubular cells to regulate calcium and phosphate metabolism.
Enhances bone remodeling by promoting osteoblastic activity and indirectly modulating osteoclastic resorption.
Increases renal tubular calcium reabsorption, reducing urinary calcium excretion and improving serum calcium.
Decreases phosphate reabsorption in renal proximal tubules, helping correct hyperphosphatemia.
Induces activation of vitamin D in kidneys enhancing intestinal calcium absorption.
Restores physiological parathyroid hormone levels in hypoparathyroid patients with sustained receptor stimulation.
Exhibits prolonged pharmacokinetics due to pegylation, providing steady hormone levels throughout the day.
Reduces the need for high doses of calcium and active vitamin D supplementation.
Modulates signaling pathways including cAMP-PKA and PLC-PKC involved in bone and mineral homeostasis.
Potentially improves bone microarchitecture and quality by balancing bone formation and resorption.
May influence cardiovascular parameters via regulation of calcium and phosphate homeostasis.
Exhibits limited immunogenicity and enzymatic degradation resistance compared to native PTH.
Provides a safe and controlled approach to hormone replacement therapy in chronic hypoparathyroidism.
Demonstrates efficacy in maintaining serum calcium without inducing rapid calcium shifts.

Therapeutic Or Clinical Uses

Treatment of adult patients with hypoparathyroidism characterized by low parathyroid hormone levels.
Management of hypocalcemia resulting from insufficient endogenous PTH production.
Restoration and maintenance of physiological balance of calcium and phosphate in the body.
Reduction of symptoms associated with hypoparathyroidism such as muscle cramps, tingling, and fatigue.
Prevention of long-term complications associated with chronically low PTH states including bone abnormalities.
Alternative to conventional therapy using high doses of oral calcium and active vitamin D analogs.
Therapy for patients intolerant or refractory to standard supplementation of calcium and vitamin D.
Facilitates dose titration to maintain serum calcium within a normal range safely.
Adjunct treatment option where reduction of supplemental calcium and active vitamin D is desired.
Post-approval use in chronic hypoparathyroidism when endogenous hormone restoration is clinically indicated.
Suitable for self-administration, improving patient adherence and quality of life.
Supports maintenance of skeletal health through balanced bone remodeling.
Treatment option with reduced risk of symptomatic hypo- or hypercalcemia compared to older PTH therapies.
Potential investigational use in other disorders of mineral metabolism where PTH analogs may be beneficial.
May help reduce hospitalization rates related to calcium imbalances in hypoparathyroid patients.

Side Or Adverse Effects

Injection site reactions including redness, swelling, or pain at the injection site.
Vasodilatory symptoms such as blood pressure drops or lightheadedness on standing (orthostatic hypotension).
Headache of varying intensity.
Gastrointestinal symptoms including diarrhea.
Back pain reported in some patients during therapy.
Hypercalcemia presenting with symptoms such as nausea, vomiting, dizziness, and confusion.
Sore throat possibly associated with systemic effects or immune response.
Hypocalcemia characterized by tingling of extremities, muscle spasms, cramps, or seizures when doses are missed or stopped abruptly.
Allergic hypersensitivity reactions including rash, hives, pruritus, and in rare cases anaphylaxis.
Hypotension immediately following injection causing dizziness or lightheadedness.
Potential development of osteosarcoma indicated by persistent bone pain or unusual lumps or swelling.
Possible digoxin toxicity when co-administered with digoxin, including arrhythmias and palpitations.
Symptoms related to electrolyte imbalance, such as irregular heartbeat or mental status changes.
Injection device-related issues, including incorrect dosing if instructions are not properly followed.
Rare immune-mediated adverse events or antibody formation impacting treatment efficacy.

Precautions

Use cautiously in patients with known risk factors for osteosarcoma including Paget’s disease or prior skeletal radiation.
Avoid use in pediatric or young adult patients with open epiphyses due to increased cancer risk.
Monitor serum calcium levels prior to initiation and regularly during treatment to detect hypo- or hypercalcemia.
Instruct patients to rotate injection sites to minimize local tissue damage.
Monitor for signs of allergic reactions and discontinue treatment if severe hypersensitivity occurs.
Use with caution in patients receiving digoxin due to risk of increased toxicity.
Evaluate concomitant medications that affect calcium metabolism such as diuretics, lithium, or phenytoin.
Adjust doses carefully to avoid serum calcium fluctuations that may cause cardiac or neurological complications.
Avoid abrupt discontinuation of therapy to prevent rebound hypocalcemia.
Pregnant and breastfeeding women should be counseled on unknown risks and monitored closely if treatment is necessary.
Patients should be educated on symptoms of calcium imbalance and advised to seek medical attention promptly.
Use under supervision with access to facilities for biochemical monitoring and management of adverse effects.
Store the medication properly and ensure correct handling of the prefilled pen to maintain drug stability.
Avoid use in individuals with known hypersensitivity to palopegteriparatide or any formulation excipients.
Patient education is essential to adhere strictly to dosing schedule and follow injection instructions.

Warnings

Risk of osteosarcoma based on preclinical animal data and observed bone changes; monitor for persistent bone pain or unusual swelling.
Serious hypercalcemia can occur; patients should be regularly monitored and symptoms promptly addressed.
Hypocalcemia risk if treatment is interrupted, missed, or doses are changed without medical supervision.
Potential for orthostatic hypotension with first doses; patients should be seated or lying down during administration initially.
Anaphylaxis and other severe allergic reactions have been reported; immediate medical intervention is required if symptoms develop.
Use of digoxin concurrently with Yorvipath may increase risk of digoxin toxicity; careful monitoring is required.
Not recommended in pediatric populations due to unknown safety and cancer risk.
Use caution in patients with a history of bone malignancies or skeletal radiation therapy.
Avoid using more than one injection per day to prevent unintended fluctuations in serum calcium.
Discard pens after 14 days to avoid dosing inaccuracies and contamination risks.
Pregnancy safety is not established; healthcare providers should discuss potential risks vs benefits.
Patients may experience dizziness or lightheadedness post-injection; instructions to minimize injury risk should be provided.
Serum calcium and phosphate levels must be regularly monitored to guide therapy adjustments.
Increases in bone alkaline phosphatase should prompt evaluation before initiating therapy.
Healthcare professionals should educate patients on recognizing symptoms of calcium imbalance and serious adverse effects.

Contraindication

Hypersensitivity to palopegteriparatide or any components of the formulation.
Children and adolescents with open epiphyses (growing bones).
Known or suspected osteosarcoma or other bone malignancies.
Patients with unexplained elevations in bone alkaline phosphatase indicating possible active bone disease.
Patients who have had prior radiation therapy to the skeleton due to increased cancer risk.
Individuals at high risk for osteosarcoma based on personal or family history of bone disease or cancer.
Pregnant women unless potential benefit outweighs risk and under strict medical supervision.
Patients with baseline hypercalcemia or unstable calcium metabolism not controlled prior to treatment.
Use in patients with significant hypersensitivity reactions to parathyroid hormone analogs.
Concurrent use with two or more injections per day due to risk of adverse calcium fluctuations.
Patients unable to adhere to monitoring or treatment administration guidelines.
Unknown safety in patients with severe renal impairment; use only if benefits clearly outweigh risk.
Not indicated for routine treatment of osteoporosis or other non-hypoparathyroid conditions.
Contraindicated in patients currently enrolled in other investigational drug studies for mineral metabolism.
Individuals with known severe reactions to any inactive ingredients of Yorvipath.

Drug Interactions

Digoxin: Increased risk of digoxin toxicity due to altered calcium levels affecting cardiac conduction.
Diuretics (thiazides and loop diuretics): May affect serum calcium concentrations and alter Yorvipath efficacy.
Lithium: Can modify parathyroid hormone secretion and calcium metabolism, requiring close monitoring.
Phenytoin: Potential alterations in vitamin D and calcium metabolism impacting drug effectiveness.
Calcium supplements and active vitamin D analogs: May require dose adjustments to prevent hypercalcemia when combined.
Osteoporosis treatments such as denosumab, alendronate, or risedronate: Possible additive or opposing effects on bone remodeling.
Other medications influencing renal calcium handling or phosphate metabolism may necessitate frequent biochemical assessment.
Medications that induce or inhibit peptidases potentially affecting metabolism of palopegteriparatide.
Concomitant corticosteroids: Potential influence on calcium absorption and bone metabolism.
Nonsteroidal anti-inflammatory drugs (NSAIDs): Limited direct interaction but may affect renal function impacting calcium homeostasis.
Drugs affecting gastrointestinal pH or absorption: May alter calcium bioavailability requiring dose reassessment.
Any drugs altering cardiovascular function could interact with vasodilatory effects of Yorvipath.
Concomitant use with other parathyroid hormone analogs is not recommended due to overlapping effects.
Patients should inform healthcare providers of all supplements and herbal products to evaluate possible interactions.
Comprehensive drug interaction checks are advised prior to initiating therapy.

Preparations Of The Drug

Yorvipath is available as a sterile, clear, colorless solution in prefilled disposable injection pens.
Three pen strengths are supplied: 168 mcg/0.56 mL (blue button), 294 mcg/0.98 mL (orange button), and 420 mcg/1.4 mL (burgundy button).
Each pen delivers multiple subcutaneous doses with labeled increments suitable for fine dose titration (6-30 mcg per injection).
Inactive ingredients include mannitol (stabilizer), metacresol (preservative), sodium hydroxide and succinic acid (pH adjusters), and water for injection.
The formulation is designed for stable extended release of active palopegteriparatide over 14 days of use after first injection.
Pens have color-coded push buttons to identify dose strength and improve user safety.
The product is supplied refrigerated (2°C to 8°C) and may be kept at room temperature (<30°C) for up to 14 days after first use.
Needles are removed after each injection and the pen is capped to protect from light and contamination.
Patients should inspect solution for clarity and discard pens if solution appears cloudy, discolored, or contains particles.
The device is designed for ease of self-administration with prior healthcare provider training recommended.
Each pen is single-patient use and discarded after 14 days to maintain drug potency and sterility.
The preparation maintains immunogenicity profiles consistent with peptide-based therapeutic agents.
Manufactured under sterile conditions by Ascendis Pharma Bone Diseases A/S with validated quality control procedures.
Storage and handling instructions emphasize avoidance of freezing and protection from heat and light.
Injection sites recommended include abdomen and front thigh, rotating sites daily to reduce injection site reactions.